Inotiv (NOTV) Expected to Announce Quarterly Earnings on Wednesday

Inotiv (NASDAQ:NOTV - Get Free Report) is projected to announce its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $121.83 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Inotiv (NASDAQ:NOTV - Get Free Report) last issued its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.16) earnings per share for the quarter. Inotiv had a negative return on equity of 15.86% and a negative net margin of 22.10%. On average, analysts expect Inotiv to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inotiv Trading Down 4.0 %

NOTV stock traded down $0.18 during mid-day trading on Friday, reaching $4.28. 453,080 shares of the stock traded hands, compared to its average volume of 562,974. Inotiv has a 52-week low of $1.23 and a 52-week high of $11.42. The stock's fifty day moving average is $4.37 and its 200-day moving average is $2.75. The company has a market cap of $111.32 million, a P/E ratio of -1.02 and a beta of 3.59. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 2.29.

Insider Activity

In other Inotiv news, Director Michael J. Harrington bought 10,000 shares of the stock in a transaction on Friday, December 6th. The shares were bought at an average price of $3.98 per share, with a total value of $39,800.00. Following the purchase, the director now directly owns 37,500 shares in the company, valued at $149,250. The trade was a 36.36 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Nigel Brown bought 7,500 shares of the company's stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average price of $4.26 per share, for a total transaction of $31,950.00. Following the acquisition, the director now directly owns 65,537 shares in the company, valued at $279,187.62. This trade represents a 12.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 71,029 shares of company stock worth $314,248 over the last 90 days. 7.80% of the stock is owned by company insiders.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.